相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
Roy O. Mathew et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Arjun Majithia et al.
CIRCULATION (2021)
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry
Suzanne V. Arnold et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
Christopher P. Cannon et al.
JAMA CARDIOLOGY (2021)
Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients
Marcelino Bermudez-Lopez et al.
CLINICAL KIDNEY JOURNAL (2021)
Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study
Bharat Poudel et al.
KIDNEY MEDICINE (2021)
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States
Christopher P. Cannon et al.
AMERICAN HEART JOURNAL (2020)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Jose Tunon et al.
EUROPEAN HEART JOURNAL (2020)
Chronic kidney disease: a high-risk group that deserves intensive lipid lowering
Christopher P. Cannon
EUROPEAN HEART JOURNAL (2020)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Jose Tunon et al.
EUROPEAN HEART JOURNAL (2020)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014
Matthew T. Mefford et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes
Talar W. Markossian et al.
CLINICAL KIDNEY JOURNAL (2019)
Dyslipidemia in patients with chronic kidney disease
Matthew R. Hager et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2017)
Meta-analysis of statins in chronic kidney disease: who benefits?
C. M. Messow et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2017)
Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates
Markus P. Schneider et al.
KIDNEY INTERNATIONAL (2015)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
Christoph Wanner et al.
KIDNEY INTERNATIONAL (2014)
Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study
David Arroyo et al.
BMC NEPHROLOGY (2014)
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
Marcello Tonelli et al.
LANCET (2012)
分享论文
